Aptorum Group Financials

APM Stock  USD 0.74  0.01  1.37%   
Based on the analysis of Aptorum Group's profitability, liquidity, and operating efficiency, Aptorum Group Ltd is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Aptorum Group's Short and Long Term Debt Total is very stable compared to the past year. As of the 24th of November 2024, Property Plant And Equipment Net is likely to grow to about 3 M, while Total Stockholder Equity is likely to drop about 21.1 M. Key indicators impacting Aptorum Group's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.180.1231
Way Up
Slightly volatile
Current Ratio1.121.1798
Notably Down
Slightly volatile
Investors should never underestimate Aptorum Group's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Aptorum Group's cash flow, debt, and profitability to make informed and accurate decisions about investing in Aptorum Group Ltd.

Net Income

(2.97 Million)

  
Understanding current and past Aptorum Group Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Aptorum Group's financial statements are interrelated, with each one affecting the others. For example, an increase in Aptorum Group's assets may result in an increase in income on the income statement.

Aptorum Group Stock Summary

Aptorum Group competes with Surrozen, Unicycive Therapeutics, Armata Pharmaceuticals, AIM ImmunoTech, and Biocardia. Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINKYG6096M1069
CUSIPG6096M106 G6096M122 G6096M114
LocationChina
Business Address17 Hanover Square,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.aptorumgroup.com
Phone44 20 8092 9299
CurrencyUSD - US Dollar

Aptorum Group Key Financial Ratios

Aptorum Group Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets24.0M44.2M21.9M20.9M20.6M23.4M
Other Current Liab2.6M3.4M4.2M6.2M2.0M2.7M
Net Tangible Assets33.1M16.3M41.8M22.7M26.1M31.0M
Retained Earnings(37.6M)(30.5M)(55.5M)(65.3M)(68.2M)(64.8M)
Accounts Payable40.1K83.3K87.4K4.2M4.8M5.0M
Cash5.2M3.5M8.1M1.9M2.0M1.9M
Net Receivables487.6K341.1K3.6M1.2M70.9K67.4K
Total Liab9.1M6.1M4.4M13.0M5.3M7.1M
Total Current Assets8.0M33.7M12.7M7.1M2.5M2.4M
Common Stock29.0M34.0M35.6M35.7M53.050.35
Net Debt1.3M(802.9K)(7.9M)5.0M1.3M1.3M
Other Assets5.0M1.7M1.3M296.2K266.6K253.3K
Other Current Assets1.5K1.4M652.5K3.7M281.4K267.4K
Net Invested Capital22.7M43.8M23.6M22.2M27.9M24.5M
Net Working Capital5.4M29.8M8.3M(5.4M)377.3K358.5K
Short Term Debt46.6K482.0K193.3K6.3M125.2K119.0K
Intangible Assets1.3M964.9K880.3K752.7K147.3K140.0K
Capital Stock29.0M34.0M35.6M35.7M53.050.35

Aptorum Group Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense3.7M243.6K93.6K146.6K121.1K115.1K
Total Revenue535.2K911.5K1.5M1.3M431.4K701.1K
Gross Profit(259.4K)(103.5K)81.9K80.1K(1.1M)(1.1M)
Operating Income(19.7M)(19.9M)(19.1M)(23.0M)(10.5M)(11.0M)
Ebit(19.7M)5.2M(20.5M)(18.8M)(10.7M)(11.3M)
Research Development6.9M11.6M10.9M9.2M5.2M7.2M
Cost Of Revenue794.5K1.0M1.5M1.2M1.5M873.0K
Income Before Tax(20.1M)4.9M(27.1M)(11.5M)(4.3M)(4.6M)
Net Income(20.9M)7.1M(25.3M)(5.3M)(2.8M)(3.0M)
Income Tax Expense737.6K(1.5M)(1.8M)(6.2M)(1.5M)(1.6M)
Minority Interest(1.5M)(3.7M)2.1M1.7M1.5M1.6M
Net Interest Income(3.7M)(243.6K)(93.6K)146.6K(121.1K)(127.2K)
Ebitda(18.4M)6.5M(19.3M)(17.6M)(9.6M)(10.1M)

Aptorum Group Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(3.5K)(4.9K)3.4K8.1K14.5K15.2K
Investments(108.1K)952.2K20.1M2.4M624.8K593.5K
Change In Cash(20.8M)(1.7M)4.6M(3.2M)(3.0M)(2.9M)
Net Borrowings16.1M(7.3M)(4.4M)(2.0M)(1.8M)(1.7M)
Depreciation1.3M1.3M1.2M1.2M1.1M957.0K
Capital Expenditures1.1M161.3K137.8K186.9K3.0K2.9K
Net Income(20.1M)4.9M(27.1M)(11.5M)(4.3M)(4.6M)
End Period Cash Flow5.3M3.6M8.3M5.0M2.0M1.9M
Change To Netincome4.5M2.8M(24.4M)8.2M7.4M7.7M
Free Cash Flow(14.5M)(16.1M)(14.8M)(12.5M)(7.7M)(8.1M)
Other Non Cash Items4.1M751.0K609.3K(5.0M)(6.2M)(5.9M)

Aptorum Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Aptorum Group's current stock value. Our valuation model uses many indicators to compare Aptorum Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aptorum Group competition to find correlations between indicators driving Aptorum Group's intrinsic value. More Info.
Aptorum Group Ltd is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, Aptorum Group's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aptorum Group by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Aptorum Group Systematic Risk

Aptorum Group's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Aptorum Group volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Aptorum Group correlated with the market. If Beta is less than 0 Aptorum Group generally moves in the opposite direction as compared to the market. If Aptorum Group Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Aptorum Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Aptorum Group is generally in the same direction as the market. If Beta > 1 Aptorum Group moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Aptorum Group Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aptorum Group's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Aptorum Group growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.043

At this time, Aptorum Group's Price Earnings To Growth Ratio is very stable compared to the past year.

Aptorum Group November 24, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Aptorum Group help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Aptorum Group Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of Aptorum Group Ltd based on widely used predictive technical indicators. In general, we focus on analyzing Aptorum Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Aptorum Group's daily price indicators and compare them against related drivers.
When determining whether Aptorum Group is a strong investment it is important to analyze Aptorum Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aptorum Group's future performance. For an informed investment choice regarding Aptorum Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptorum Group Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptorum Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.62)
Revenue Per Share
0.095
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.32)
Return On Equity
(0.37)
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptorum Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptorum Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptorum Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.